Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Zhang, Rongli  [Clear All Filters]
Journal Article
Shen Y, Zhang T, Zhang L, Zhen S, Chen Z, Zhang R, Yang D, Wei J, He Y, Jiang E, et al. Allogeneic stem cell transplantation can prolong the survival of patients with NUP98-rearranged acute myeloid leukemia. Bone Marrow Transplant. 2023.
Guo W, Liu X, Wang M, Liu J, Cao Y, Zheng Y, Zhai W, Chen X, Zhang R, Ma Q, et al. Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia. Hematology. 2023;28(1):2205739.
Chen X, Ma Y, Zhang R, Zhai W, Ma Q, Pang A, Yang D, Wei J, He Y, Song Z, et al. Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation. Hematology. 2023;28(1):2212943.
Cao Y, Gong X, Feng Y, Wang M, Hu Y, Liu H, Liu X, Qi S, Ji Y, Liu F, et al. The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. Am J Hematol. 2023.
Cao Y, Wang M, Wang F, Guo W, Ma Y, Li X, He Y, Pang A, Zhang R, Zhai W, et al. Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study. Chin Med J (Engl). 2024.
Zheng X, Gao H, Lu N, Wang M, Zhang H, Zheng Y, Shen B, Cao Y, Chen X, Zhai W, et al. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Ann Hematol. 2023.
Chen X, Zheng X, Lu N, Zhang R, Zhai W, Ma Q, Pang A, Yang D, Wei J, He Y, et al. Explorations of post-gDLI low-dose cyclophosphamide for preventing severe aGVHD. Int Immunopharmacol. 2023;125(Pt A):111165.
Li J, Liu Y, Wang J, Wang Y, Pang A, Yang D, Chen X, Zhang R, Wei J, Ma Q, et al. Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation. Sci Rep. 2024;14(1):5178.
Zhao F, Shi Y, Chen X, Zhang R, Pang A, Zhai W, Yang D, He Y, Feng S, Zhang P, et al. Higher Dose of CD34 cells Promotes Early Reconstitution of Natural Killer Cells and Is Associated with Better Outcomes After Unmanipulated Hematopoietic Stem Cell Transplantation for Myeloid Malignancies. Transplant Cell Ther. 2022.
Wang J, Wang Q, Zhang H, He Y, Huang Y, Zhang R, Wei J, Ma Q, Pang A, Yang D, et al. Moderate to severe marrow fibrosis as a more advanced risk factor for MDS and MDS-AML patients with excess of blasts receiving allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021.
Shen Y, Yang D, Zhang R, Chen X, Ma Q, Wei J, Zhai W, Pang A, He Y, Jiang E, et al. The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation. Front Oncol. 2023;13:1256043.
Zhang H, Zheng X, Guo W, Xia Y, Zhang R, Zhai W, Chen X, Ma Q, Yang D, Wei J, et al. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol. 2024;13(1):16.
Lv M, Liu L, He Y, Yang D, Ma Q, Pang A, Zhai W, Wei J, Huang Y, Chen X, et al. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease. Br J Haematol. 2023.
Zhang S, Zhang P, Wang Z, Liu L, He Y, Jiang E, Wei J, Yang D, Zhang R, Zhai W, et al. Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases. Future Microbiol. 2019.
Chen J, Pang A, Zhao Y, Liu L, Ma R, Wei J, Chen X, He Y, Yang D, Zhang R, et al. Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology. 2022;27(1):293-299.
Shen Y, Zhang L, Zhang X, Zhang T, Jiang E, Feng S, He Y, Zhang R. Treatment with the combination of rituximab and intravenous γ globulin is effective in promoting engraftment in donor specific antibody positive patients receiving myeloablative conditioning haploidentical stem cell transplantation. Transplant Cell Ther. 2023.
Gao H, Wang J, Zheng X, Pei X, Zheng Y, Zhai W, Zhang R, Chen X, Ma Q, Wei J, et al. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort. Front Cell Infect Microbiol. 2024;14:1324019.